Skip to main content

Table 7 Genes that have a general association (P-value < 0.05) with the progression-free glioblastoma survival

From: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival

Gene Symbol Probe Identifier P-value Hazard Ratio1 Relevant literature references
Pla2g7 206214_at <.0001 0.11 (0.05-0.23) [119]O
Pdgfb 216061_x_at <.0001 0.18 (0.09-0.35) [28]G
Calm2 207243_s_at 0.0011 0.22 (0.09-0.54) [28]G
Timp3 201148_s_at <.0001 0.26 (0.16-0.41) [26]G
Agpat1 215535_s_at <.0001 0.27 (0.15-0.51) n/a
Ifngr1 202727_s_at <.0001 0.32 (0.19-0.53) [27]G
Pvr 214444_s_at <.0001 0.32 (0.19-0.54) [26]G
Ndufv1 208714_at 0.0002 0.33 (0.19-0.59) n/a
Fgfr2 211401_s_at <.0001 0.39 (0.26-0.57) [26]G
E2f3 203693_s_at <.0001 0.42 (0.29-0.60) [28]G
Pold2 201115_at 0.0007 0.43 (0.27-0.70) [26]G
Calm3 200622_x_at 0.0001 0.43 (0.28-0.67) [28]G
Tp53 211300_s_at <.0001 0.43 (0.29-0.64) [25]G
Raf1 201244_s_at 0.0141 0.46 (0.25-0.85) [26]G
Pknox2 219046_s_at <.0001 0.46 (0.33-0.62) [120]O
App 214953_s_at 0.0016 0.47 (0.30-0.75) [24]G
Fstl1 208782_at <.0001 0.47 (0.35-0.62) [25]G
Camk2b 211483_x_at 0.0008 0.54 (0.38-0.77) [28]G
Pten 204053_x_at 0.0003 0.60 (0.46-0.79) [26]G
Mdm2 217373_x_at <.0001 0.66 (0.57-0.76) [26]G
Ccnd1 208711_s_at 0.0273 0.80 (0.66-0.98) [28]G
Hspa1a/Hspa1b 202581_at 0.0529 0.82 (0.67-1. 00) [24]G
Cd24 208650_s_at 0.0069 0.85 (0.75-0.95) [121]O
Clec2b 209732_at 0.06452 1.19 (0.99-1.44) [122]O
Cav2 203324_s_at 0.0024 1.25 (1.08-1.44) [123]O
Snx10 218404_at <.0001 1.34 (1.16-1.57) [124]O
Wee1 215711_s_at 0.0083 1.37 (1.08-1.74) [27]G
Hras 212983_at 0.08022 1.49 (0.95-2.33) [85]G
Mns1 219703_at 0.0053 1.51 (1.13-2.02) n/a
Ppp1r15a 37028_at 0.011 1.54 (1.10-2.15) n/a
App 211277_x_at 0.08112 1.56 (0.95-2.56) [24]G
Fadd 202535_at 0.09342 1.57 (0.93-2.65) [125]O
Pik3r1 212239_at 0.018 1.60 (1.08-2.36) [20]G
Mmp14 217279_x_at 0.0182 1.66 (1.09-2.52) [24]G
Mtap 204956_at 0.0016 1.66 (1.21-2.27) [26]G
Il13ra1 211612_s_at 0.0003 1.72 (1.28-2.32) [24]G
Kcnj13 210179_at 0.0235 1.74 (1.08-2.82) [126]O
Clip3 212358_at 0.0022 1.75 (1.22-2.50) n/a
Aanat 207225_at 0.0114 1.78 (1.14-2.79) [127]O
Camk2g 214322_at 0.0024 1.86 (1.24-2.78) [56]G
Prkca 215195_at 0.0005 1.90 (1.32-2.73) [28]G
Kdm6b 41386_i_at 0.0003 2.03 (1.39-2.96) n/a
Zfy 207246_at 0.0016 2.06 (1.31-3.22) [128]O
Smarcb1 212167_s_at 0.0004 2.06 (1.38-3.07) [26]G
Utp20 209725_at <.0001 2.08 (1.46-2.98) n/a
Igl@ 211655_at 0.0209 2.22 (1.13-4.38) [129]O
Atf5 204998_s_at <.0001 2.31 (1.72-3.11) [130]G
Shox 207570_at <.0001 2.66 (1.73-4.07) [24]G
Loc283079 215929_at 0.0071 2.73 (1.31-5.69) n/a
Ung 202330_s_at 0.0001 2.79 (1.66-4.68) [27]G
Hnrnpd 213359_at <.0001 2.94 (1.91-4.52) n/a
Camk2b 209956_s_at <.0001 3.02 (2.13-4.29) [28]G
Timp3 201150_s_at <.0001 3.10 (1.88-5.11) [26]G
Nras 202647_s_at <.0001 3.93 (2.60-5.95) [28]G
Paics 214664_at <.0001 5.28 (3.13-8.91) [66]O
  1. n/a, No association with any type of cancer found in literature;
  2. 1 Hazard ratio estimate (95% confidence interval);
  3. 2 Borderline significant (P-value < 0.1) included for completeness;
  4. G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
  5. O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.